Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib

Cited by (208)

Items 101–200 of 208

1. Proton density fat fraction for diagnosis of metabolic dysfunction–associated steatotic liver disease
   Nikolaos Panagiotopoulos, Tanya J. Wolfson, David T. Harris, Danielle Batakis, Rashmi M. Agni, Lael Ceriani, Yesenia Covarrubias, Gavin Hamilton, Michael S. Middleton, Vitor F. Martins et al. · 2025 · Hepatology
2. Evaluation of proton density fat fraction (PDFF) obtained from a vendor-neutral MRI sequence and MRQuantif software
   T. Orcel, H. T. Chau, Bruno Turlin, Julien Chaigneau, Élise Bannier, Philippe Otal, Éric Frampas, A Leguen, Anne Boulic, Hervé Saint‐Jalmes et al. · 2023 · European Radiology
3. Multiparametric ultrasound imaging for early‐stage steatosis: Comparison with magnetic resonance imaging‐based proton density fat fraction
   Jihye Baek, Lokesh Basavarajappa, Ryan Margolis, Leroy Arthur, Junjie Li, Kenneth Hoyt, Kevin J. Parker · 2023 · Medical Physics
4. End-points for drug treatment in NASH
   Leon Anton Adams · 2019 · Hepatology International
5. Challenges and opportunities in drug development for nonalcoholic steatohepatitis
   Matthias Ocker · 2020 · European Journal of Pharmacology
6. Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
   Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye‐Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae-Been Im et al. · 2022 · International Journal of Molecular Sciences
7. Spinosin inhibits activated hepatic stellate cell to attenuate liver fibrosis by targeting Nur77/ASK1/p38 MAPK signaling pathway
   Gang Lin, Weibin Li, Wenbin Hong, Desheng Zhu, Hongyu Hu, Jiqiang Fu, Yanfang Gao, Shuaijie Chen, Dajun Chai, Jin-Zhang Zeng · 2023 · European Journal of Pharmacology
8. Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
   Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi · 2021 · Journal of Medical Ultrasonics
9. The many pathways driving liver inflammation in MASH
   Herbert Tilg, Timon Erik Adolph, Stefano Romeo, Rohit Seth Loomba · 2026 · Cell Metabolism
10. Evaluation of Quantitative Imaging Biomarkers for Early‐phase Clinical Trials of Steatohepatitis in Adolescents
    Nidhi P. Goyal, Mary Catherine Sawh, Patricia Ugalde‐Nicalo, Jorge Eduardo Angeles, James A. Proudfoot, Kimberly P. Newton, Michael S. Middleton, Claude B. Sirlin, Jeffrey B. Schwimmer · 2019 · Journal of Pediatric Gastroenterology and Nutrition
11. Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
    C. Vikneshwaran Chandra Kumar, Ruben Skantha, Wah‐Kheong Chan · 2022 · Therapeutic Advances in Endocrinology and Metabolism
12. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease
    Kento Imajo, Yasushi Honda, Masato Yoneda, Satoru Saito, Atsushi Nakajima · 2020 · Journal of Medical Ultrasonics
13. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective
    Erica Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Rao Surabhi, Srinivasa R. Prasad, Venkata Subbiah Katabathina · 2025 · Radiographics
14. Performance of Imaging Techniques in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease in Children: A Systematic Review and Meta-Analysis
    Qun Yu, Yiwei Liu, Peipei Hu, Feng Gao, Guoqing Huang · 2022 · Frontiers in Pediatrics
15. Reproducibility of hepatic MR elastography across field strengths, pulse sequences, scan intervals, and readers
    Hye Jin Kim, Bohyun Kim, Hyun Jeong Yu, Jimi Huh, Jei Hee Lee, Seung Soo Lee, Kyung Won Kim, Jai Keun Kim · 2019 · Abdominal Radiology
16. Predicting NASH response with liver fat: Are we back to square one?
    Vincent Wai‐Sun Wong · 2019 · Journal of Hepatology
17. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
    Hunter, Harriet, de Gracia Hahn, Dana, Duret, Amedine, Im, Yu Ri, Cheah, Qinrong, Dong, Jiawen, Fairey, Madison, Hjalmarsson, Clarissa, Li, Alice, Lim, Hong Kai et al. · 2020 · eLife
18. Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease
    Masahiro Ogawa, Tatsuo Kanda, Teruhisa Higuchi, Hiroshi Takahashi, Tomohiro Kaneko, Naoki Matsumoto, Kazushige Nirei, Hiroaki Yamagami, Shunichi Matsuoka, Kazumichi Kuroda et al. · 2019 · International Journal of Medical Sciences
19. Changes of liver stiffness measured by magnetic resonance elastography during direct‐acting antivirals treatment in patients with chronic hepatitis C
    Mayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Shuhei Sekiguchi, Leona Osawa, Kenta Takaura et al. · 2020 · Journal of Medical Virology
20. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes
    Ebaa Al‐Ozairi, Mohammad Irshad, Jumana AlKandari, Anant Mashankar, Dherar Alroudhan, Carel Wynand le Roux · 2024 · Diabetes Obesity and Metabolism
21. Recent advances in NAFLD: current areas of contention
    Erica Jennison, Christopher D. Byrne · 2023 · Faculty Reviews
22. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD
    Yamini Natarajan, Rohit Seth Loomba · 2021 · Journal of Clinical and Experimental Hepatology
23. Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis
    Yang Zhi, Yinuo Dong, Xiaoyun Li, Wei Zhong, Xiaohong Lei, Jie Ting Tang, Yimin Mao · 2024 · Diabetes/Metabolism Research and Reviews
24. Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data
    Meng-Yuan Miao, Wen-Wen Han, Jie‐Qiong Lyu, Zhong‐Yue Liu, Wei Jiang, Zheng Zhang, Zhengbao Zhu, Li‐Qiang Qin, Guo‐Chong Chen · 2025 · American Journal of Obstetrics and Gynecology
25. Donor Evaluation Protocol for Live and Deceased Donors
    Pankaj Puri, Abhinav Kumar, Mohd Qaleem · 2023 · Journal of Clinical and Experimental Hepatology
26. Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness
    Jessica Dahmus, Breianna L. Hummer, Gloriany Rivas, Kathryn H. Schmitz, Stephen Hugh Caldwell, Curtis Kent Argo, Ian Roy Schreibman, Jonathan G. Stine · 2023 · Digestive Diseases and Sciences
27. Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression
    Bradley, Christopher R., Cox, Eleanor F., Palaniyappan, Naaventhan, Aithal, Guruprasad P., Francis, Susan T., Guha, Indra Neil · 2022 · European Radiology Experimental
28. Novel Imaging Technology for Biomedical and Clinical Application
    Jingyi Dong, Kai Huang, Sicen Lai, Yihao Peng, Yuancheng Liu, X.P. Li, Lingjia Hao, Jiayi Li, Jiaqi Huang, Zeyu Chen et al. · 2025 · Phenomics
29. Comparison of navigator-gated and breath-held image acquisition techniques for multi-echo quantitative dixon imaging of the liver in children and young adults
    Leah A. Gilligan, Jonathan R. Dillman, Jean A. Tkach, Andrew T. Trout · 2019 · Abdominal Radiology
30. Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies
    Dhaval N. Gosalia, Vlad Ratziu, Filip Stanicic, Djurdja Vukicevic, Vladimir Zah, Nadege Gunn, Dina L. Halegoua-DeMarzio, Tram T. Tran · 2022 · Diagnostics
31. Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease
    Winston Dunn, Laurent Castéra, Rohit Seth Loomba · 2023 · Clinics in Liver Disease
32. Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis
    Rohit Seth Loomba, Peter C. Daniel, Youxin Wang, Ricki Bettencourt, Egbert V. Madamba, Harris Siddiqi, Lisa Richards, Mildred D. Gottwald, Shibao Feng, Maya Margalit et al. · 2026 · Clinical Gastroenterology and Hepatology
33. Detection of moderate hepatic steatosis on contrast-enhanced dual-source dual-energy CT: Role and accuracy of virtual non-contrast CT
    Roberta Catania, Leo Jia, Maryam Haghshomar, Frank H. Miller, Amir Ali Borhani · 2024 · European Journal of Radiology
34. Associations of Plasma CD36 and Body Fat Distribution
    Yeli Wang, Manja Koch, Romina di Giuseppe, K C Evans, Jan Borggrefe, Ute Nöthlings, Aase Handberg, Majken K. Jensen, Wolfgang Lieb · 2019 · The Journal of Clinical Endocrinology & Metabolism
35. The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial
    Dimitar Tonev, Elizabeth Shumbayawonda, Louise Ann Tetlow, Laura Herdman, Marika French, Soubera Rymell, Helena B. Thomaides-Brears, Filipe Caseiro‐Alves, Miguel S. Castelo-Branco, Carlos Ferreira et al. · 2020 · JMIR Research Protocols
36. Early assessment of nonalcoholic fatty liver disease using multiparametric ultrasound imaging
    Lokesh Basavarajappa, Shreya Reddy, Haowei Tai, Jane J. Song, Girdhari Rijal, Kevin J. Parker, Kenneth Hoyt · 2020 · IEEE International Ultrasonics Symposium
37. How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review
    You-Wei Li, Yang Jiao, Na Chen, Qiang Gao, Yu‐Kun Chen, Yuan‐Fang Zhang, Qi-Ping Wen, Zongming Zhang · 2022 · World Journal of Clinical Cases
38. Non-invasive diagnosis and prognosis of MASH with fibrosis F2-F3: In need for a tailored, accessible, and affordable solution for the 21st century public health epidemic
    Konstantinos Stefanakis, Jacob George, Christos Socrates Mantzoros · 2025 · Metabolism
39. Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
    Lin Meng, Fayu Lu, Bing Zhang, Yujia Ma, Jian Gao · 2025 · Cell Communication and Signaling
40. Early Detection of Liver Steatosis using Multiparametric Ultrasound Imaging
    Lokesh Basavarajappa, Junjie Li, Haowei Tai, Jane J. Song, Kevin J. Parker, Kenneth Hoyt · 2021 · IEEE International Ultrasonics Symposium
41. Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling
    Amrik Shah, Leigh MacConell, Alexander Liberman, Adrian M. Di Bisceglie, David Shapiro · 2025 · Alimentary Pharmacology & Therapeutics
42. Practical approach to quantitative liver and pancreas MRI in children
    Justine M. Kemp, Adarsh Ghosh, Jonathan R. Dillman, Rekha Krishnasarma, Mary Kate Manhard, Aaryani Tipirneni‐Sajja, Utsav Shrestha, Andrew T. Trout, Cara E. Morin · 2025 · Pediatric Radiology
43. The Varied Modalities of Liver Elastography and How Each Fits Into a Hepatology Practice
    Hanyu Jiang, Kathryn Jane Fowler, Mustafa Rifaat Bashir · 2021 · Clinical Liver Disease
44. Application and research progress of magnetic resonance proton density fat fraction in metabolic dysfunction-associated steatotic liver disease: a comprehensive review
    Hongyan Qi, Shanshan Jiang, Jiang Nan, Hang Guo, Cai Cheng, Xin He, Hongyang Jin, Rongfan Zhang, Junqiang Lei · 2024 · Abdominal Radiology
45. Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model
    Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo · 2025 · Radiology
46. Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
    Grit Andersen, Leona Plum‐Mörschel, Paul D. Hockings, Anni Morsing, Mads Sundby Palle, Olivia Svolgaard, Anne Flint · 2020 · Advances in Therapy
47. Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease
    Yushi Tsujita, Keitaro Sofue, Eisuke Ueshima, Yoshiko R. Ueno, Masatoshi Hori, Takamichi Murakami · 2022 · Magnetic Resonance in Medical Sciences
48. Simultaneous liver steatosis, fibrosis and iron deposition quantification with mDixon quant based on radiomics analysis in a rabbit model
    Zou Liqiu, Hao Zhang, Qing Wang, Wenxin Zhong, YaNan Du, Haifeng Liu, Wei Xing · 2022 · Magnetic Resonance Imaging
49. Exploring the potential of drug repurposing for liver diseases: A comprehensive study
    Fares E.M. Ali, Mustafa Ahmed Abdel‐Reheim, Emad H. M. Hassanein, Mostafa K. Abd El‐Aziz, Hanan S. Althagafy, Khalid S.A. Badran · 2024 · Life Sciences
50. Biologically active compounds of plant origin in medicine
    Mirosława Chwil, Michał S. Skoczylas · 2021
51. Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy
    Xiaoxia Wang, Yuchuan Tan, Daihong Liu, Hesong Shen, Yongchun Deng, Yong Tan, Lei Wang, Yipeng Zhang, Xin Ma, Xiaohua Zeng et al. · 2022 · European Radiology
52. Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
    Suzanne R. Sharpton, Ondřej Podlaha, Jen-Chieh Chuang, Yevgeniy Gindin, Robert P. Myers, Rohit Seth Loomba · 2022 · Therapeutic Advances in Gastroenterology
53. Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
    Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura et al. · 2025 · Scientific Reports
54. Morphometric Quantification of Steatosis and Fibrosis in Metabolic Liver Disease Associated With Type 2 Diabetes
    O Fourati, Pauline Manchon, Philippe Garteiser, Laurent Castéra, Marco Dioguardi Burgio, Bernard E. VAN BEERS, Pierre Bédossa, Miguel Albuquerque, Thierry Poynard, Cédric Laouenan et al. · 2025 · Clinical Gastroenterology and Hepatology
55. Design, synthesis and biological evaluation of Alisol B derivatives for potential treatment of non-alcoholic steatohepatitis
    Nai-Rong Yu, Suling Huang, Zhen‐Tao Deng, Jiayue Wang, Yu Shen, Ying Leng, Qin‐Shi Zhao · 2025 · Bioorganic Chemistry
56. The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial
    Maneerat Chayanupatkul, Waleerat Sawatdee, Anuchit Chutaputti, Pisit Tangkijvanich · 2022 · Journal of Integrative and Complementary Medicine
57. Impact of alcohol consumption on metabolic dysfunction‐associated fatty liver disease development and remission: A longitudinal cohort study
    Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Shota Fujmoto, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida et al. · 2024 · European Journal of Clinical Investigation
58. This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol
    Anja M. Fischer, Nazim Lechea, Harvey O. Coxson · 2024 · Seminars in Liver Disease
59. Communicable and noncommunicable liver disease in HIV
    Stefan Mauss, Christoph Boesecke · 2021 · Current Opinion in HIV and AIDS
60. Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
    Qianjiao Liu, Hong-Fang Nie, Hengtian Xu, Pingxian Wang, Pinggui Lei · 2020 · Korean Journal of Radiology
61. MRI-Based Assessment of Etiology-Specific Sarcopenia Phenotypes in Chronic Liver Disease: A Comparative Study of MASH and Viral Hepatitis
    Mika Yasutomi, Kazuhiro Saito, Yoichi Araki, Katsutoshi Sugimoto, Daisuke Yoshimaru, Shuhei Shibukawa, Masanori Ishida · 2026 · Diagnostics
62. From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis
    Almir Fajkić, Yun Wah Lam, Rijad Jahić, Ivan Ćavar, Antonio Markotić, Andrej Belančić · 2026 · Current Issues in Molecular Biology
63. Magnetic Resonance Elastography of Liver: Current Status and Future Directions
    Argha Chatterjee, Frank H. Miller, Emily Pang · 2024 · Journal of Gastrointestinal and Abdominal Radiology
64. Fibrosis Assessment in Patients with NAFLD
    Victor de Lédinghen · 2020 · Springer eBooks
65. Noninvasive Assessment of Liver Fibrosis by Magnetic Resonance Elastography in Patients with Rheumatic Disease on Long-Term Methotrexate Treatment
    ArindamNandy Roy, AnjaniKumar Darapureddy, YarramAshok Kumar · 2022 · Indian Journal of Rheumatology
66. Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria
    Lili Zhuo, Jiali Xu, Ningning You, Liyan Wang, Yu Song, Yan Luo, Junping Shi · 2020 · Medicine
67. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis
    Dimitrios A. Koutoukidis, Elizabeth M. Morris, John A. Henry, Yusra Shammoon, Matthew Zimmerman, Moscho Michalopoulou, Susan Ann Jebb, Paul N Aveyard · 2021 · PLoS ONE
68. Effect of noise and estimator type on bias for analysis of liver proton density fat fraction
    Edward M. Lawrence, Nathan T. Roberts, Diego Hernando, Lu Mao, Scott Brian Reeder · 2020 · Magnetic Resonance Imaging
69. Method for measuring time waveforms of minute sinusoidal displacements using continuous waves with a network analyzer
    Yuya Komatsu, Shohei Mori, Mototaka Arakawa, Hiroshi Kanai · 2024 · Japanese Journal of Applied Physics
70. Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation
    Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding · 2026 · Frontiers in Pharmacology
71. Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial
    Madeline N. Erlich, Diana Ghidanac, Sonia Blanco Mejía, Sabrina Ayoub‐Charette, Claudia Vittes Combe, Tauseef Ahmad Khan, Devina P. Ramdath, Heather Crewson, Amanda Beck, C. J. Silva et al. · 2026 · Nutrients
72. Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in metabolic dysfunction–associated steatohepatitis (MASH)
    Arun Jayant Sanyal, Manal F. Abdelmalek, Rohit Seth Loomba · 2026 · Hepatology
73. Assessment of hepatic fat content and prediction of myocardial fibrosis in athletes by using proton density fat fraction sequence
    Tao Liu, Ping Dong, Jin‐Rong Zhou, Jing Chen, Qian-Feng Luo, Shuang Long, Jiali Li, Dong Chen, Yuansheng Li · 2023 · La radiologia medica
74. Multifactorial Aspects Influencing Non-Alcoholic Fatty Liver Disease (Nafld)
    Rachana Raveendran Rachana Raveendran, A. Josephine Josephine. A, P Kalaiselvi Kalaiselvi P, Sureka Varalakshmi, Kanchana S B Kanchana SB, Thahira Abdulla Abdulla Thahira, Swathi T Swathi T, Pinchulatha K Pinchulatha K, Ambili PV Ambili PV, D Roy · 2023 · Journal Of Advanced Zoology
75. Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
    Centura R. Anbarasu, Sophia M. Williams-Perez, Ernest Ramsay Camp, Derek J. Erstad · 2024 · Cancers
76. Inter-visit and inter-reader reproducibility of multi-parametric diffusion-weighted MR imaging in longitudinally imaged patients with metabolic dysfunction-associated fatty liver disease and healthy volunteers.
    Anton Volniansky, Thierry L Lefebvre, Merve Kulbay, Boyan Fan, Emre Aslan, Kim‐Nhien Vu, Emmanuel Montagnon, Bich Nguyen, Giada Sebastiani, Jeanne‐Marie Giard et al. · 2024 · Magnetic Resonance Imaging
77. Applications of Fat Mapping
    Hermien E. Kan, Dimitrios C. Karampinos, Jürgen Machann · 2020 · Advances in magnetic resonance technology and applications
78. Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
    Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi · 2023 · Choonpa Igaku
79. Noninvasive Chronic Liver Disease Staging and Pregnancy Outcome Measures Are Not Limited to Albumin Bilirubin and Aspartate Aminotransferase to Platelet Ratio Index Scorings System
    Ranjeet Singh Mahla · 2019 · The American Journal of Gastroenterology
80. FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic “
    Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2020 · Preprints.org
81. A preliminary study of liver fat quantification using reported longitudinal ultrasound speed of sound and attenuation parameters
    Juvenal Ormachea, Kevin J. Parker · 2021 · arXiv (Cornell University)
82. Imaging Biomarkers in Metabolic Dysfunction Associated Steatotic Liver Disease
    Deniz Gül, Michael Pavlides · 2025 · Current Hepatology Reports
83. MR Based-Imaging Biomarkers in NAFLD/NASH
    Michael Pavlides · 2020 · Springer eBooks
84. Magnetresonanzelastographie der Leber
    Michaela Plaikner, Christian Kremser, André Viveiros, Heinz Zoller, Benjamin Henninger · 2020 · Der Radiologe
85. Serum fibroscores APRI, FIB-4 and fibroscan in assessment of liver fibrosis in alcoholic associated liver disease
    B. Balakasi Naik, Babu Suresh Kumar, Sultan Nawahirsha Pughazhendhi · 2021 · International Journal of Advances in Medicine
86. Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients received neoadjuvant chemotherapy
    Xiaoxia Wang, Yuchuan Tan, Jun Qi, Daihong Liu, Hesong Shen, Yong Tan, Lei Wang, Yipeng Zhang, Xin Ma, Jiazheng Wang et al. · 2021 · Research Square
87. Ultrasound-based techniques for noninvasive diagnosis of liver steatosis in nonalcoholic fatty liver disease
    Fang Liu · 2021 · World Chinese Journal of Digestology
88. Modelling non-alcoholic fatty liver disease using patient derived liver stem cells and hepatic organoids
    Yee Siang Lim · 2019
89. Functional Imaging of the Liver
    Simona Picchia, Martina Pezzullo, Maria Antonietta Bali, Septian Hartono, Choon Hua Thng, Dow‐Mu Koh · 2020 · Medical radiology
90. Normalization of γ-glutamyl Transferase Levels is Associated with Better Metabolic Control in Individuals with Nonalcoholic Fatty Liver Disease
    Qianqian Ma, Xianhua Liao, Congxiang Shao, Yansong Lin, Tingfeng Wu, Yanhong Sun, Shi‐Ting Feng, Junzhao Ye, Bihui Zhong · 2020 · Research Square
91. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease
    Kento Imajo, Yasushi Honda, Masato Yoneda, Satoru Saito, Atsushi Nakajima · 2022 · Choonpa Igaku
92. Longitudinal ultrasound imaging and network modeling in rats reveal sex-dependent suppression of liver regeneration after resection in alcoholic liver disease
    Benjamin Barnhart, Toshiki Kan, Ankita Srivastava, Corinne E. Wessner, John Waters, Manju Ambelil, John Robert Eisenbrey, Jan B. Hoek, Rajanikanth Vadigepalli · 2023 · Frontiers in Physiology
93. NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: MODERN IMAGING MODALITIES
    Alina Yu. Babenko, M. Yu. Laevskaya, Мелтонян Ася Робертовна, Савченков Юрий Николаевич, Г. Е. Труфанов · 2023 · Translational Medicine
94. Neue MRT-Verfahren zur NASH-Diagnostik
    Carolina Río Bártulos, Thomas J. Vogl, Philipp Wiggermann · 2023 · Gastro-News
95. Hepatic fat infiltration and clinical indicators in polycystic ovary syndrome: insights from MRI HISTO sequences
    Ling Min, Shuting Lu, Runrong Chen, Jiangnian Gong, Bin Tian, Yingfen Qin, Jia Zhou, Zisan Zeng · 2025 · Reproductive BioMedicine Online
96. ASK1 inhibition by selonsertib attenuates elastase-induced emphysema in mice
    Priscilla Cristine de Oliveira Mineiro, Vanderlei da Silva Fraga‐Junior, Aline de Oliveira Pontes Cardoso, Christopher M. Waters, Christina Maeda Takiya, Claudia Farias Benjamim, Helber da Maia Valença, Manuella Lanzetti, João Alfredo Moraes, Samuel Santos Valença · 2025 · Life Sciences
97. MRI-based Assessment of Disease-Specific Risk Profiles for Sarcopenia in Chronic Liver Disease
    Mika Yasutomi, Kazuhiro Saito, Yoichi Araki, Katsutoshi Sugimoto, Daisuke Yoshimaru, Shuhei Shibukawa, Masanori Ishida · 2025 · Research Square
98. Additional file 1 of Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease
    Ma, Qianqian, Liao Xianhua, Congxiang Shao, Lin, Yansong, Tingfeng Wu, Sun, Yanhong, Shiting Feng, Junzhao Ye, Bihui Zhong · 2021 · Figshare
99. Clinical Application of Magnetic Resonance Imaging in the Diagnosis of NAFLD
    Jifei Deng, Shizhao Ou, Lijuan Lai, Derek Corica, Lijun Dong, Yujiang Fang, Guojun Song · 2026 · Current Medical Imaging Formerly Current Medical Imaging Reviews
100. Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography
     Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, M. Yamashita, Masahiro Umemura, Kazuyoshi Ohta et al. · 2026 · Journal of clinical lipidology